Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma
Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma. Eighteen patients were treated in one of two consecutive trials. Thirteen pati...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2003-12, Vol.21 (23), p.4407-4412 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4412 |
|---|---|
| container_issue | 23 |
| container_start_page | 4407 |
| container_title | Journal of clinical oncology |
| container_volume | 21 |
| creator | KHOURI, Issa F LEE, Ming-S CHAMPLIN, Richard E SALIBA, Rima M GU JUN FAYAD, Luis YOUNES, Anas PRO, Barbara ACHOLONU, Sandra MCLAUGHLIN, Peter KATZ, Ruth L |
| description | Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma.
Eighteen patients were treated in one of two consecutive trials. Thirteen patients underwent a conditioning regimen of fludarabine (30 mg/m2 daily for 3 days), cyclophosphamide (750 mg/m2 daily for 3 days), and high-dose rituximab. For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m2 daily for 4 days), fludarabine (30 mg/m2 daily for 2 days), and cytarabine (1,000 mg/m2 daily for 2 days). Tacrolimus and methotrexate were used for graft-versus-host disease prophylaxis.
The median age was 56.5 years. Patients underwent a median of three prior chemotherapy regimens. Prior autologous transplantation failed in five (28%) patients and 16 (89%) had chemosensitive disease. Donor cell engraftment occurred in all patients. Eight patients (44%) required no platelet or RBC transfusion, and acute graft-versus-host disease of greater than grade 2 did not develop in any patient. The day-100 mortality was 0%. Complete remission (CR) occurred in 17 patients. Three patients progressed, and one was reinduced into continuous CR with donor lymphocyte infusion. With a median follow-up period of 26 months, the actuarial probability of current-event-free-survival at 3 years was 82% (95% CI, 65% to 99%).
Our data suggest that nonablative allogeneic transplantation is a safe and potentially effective strategy for patients with relapsed and chemosensitive mantle-cell lymphoma. |
| doi_str_mv | 10.1200/JCO.2003.05.501 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71426878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71426878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-5b8f96f6d795e5adc3662ac20a01970a38d965d3fb58c0e8a85c8de5c5e402123</originalsourceid><addsrcrecordid>eNpF0U1PGzEQgGELgSAFzr1Ve4GeNvHX7DrHKCr9UCgSpVIPSNbEO0sWedepvaHi39cokTjN5ZmR9Zqxj4JPheR89mN5N81TTTlMgYsjNhEg67KuAY7ZhNdKlsKoP2fsQ0rPnAttFJyyM6ErDVqJCXv8GQZcexy7FyoW3ocnGqhzxa-R-nJJ3hcPEYe09TiMGYWhaEMsFs0LDo6a2T25XYw0jMVtBp72K6vXfrsJPV6wkxZ9osvDPGe_b748LL-Vq7uv35eLVem0FGMJa9POq7Zq6jkQYONUVUl0kiMX85qjMs28gka1azCOk0EDzjQEDkhzKaQ6Z9f7u9sY_u4ojbbvkssvwYHCLtlaaFmZ2mQ420MXQ0qRWruNXY_x1Qpu34LaHNS-BbUcbA6aNz4dTu_WPTXv_lAwg6sDwOTQt7mW69K7A1VlpbL7vHeb7mnzr4tkU4_e57PSPrsghZXKap2_7D_PZ4tj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71426878</pqid></control><display><type>article</type><title>Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>KHOURI, Issa F ; LEE, Ming-S ; CHAMPLIN, Richard E ; SALIBA, Rima M ; GU JUN ; FAYAD, Luis ; YOUNES, Anas ; PRO, Barbara ; ACHOLONU, Sandra ; MCLAUGHLIN, Peter ; KATZ, Ruth L</creator><creatorcontrib>KHOURI, Issa F ; LEE, Ming-S ; CHAMPLIN, Richard E ; SALIBA, Rima M ; GU JUN ; FAYAD, Luis ; YOUNES, Anas ; PRO, Barbara ; ACHOLONU, Sandra ; MCLAUGHLIN, Peter ; KATZ, Ruth L</creatorcontrib><description>Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma.
Eighteen patients were treated in one of two consecutive trials. Thirteen patients underwent a conditioning regimen of fludarabine (30 mg/m2 daily for 3 days), cyclophosphamide (750 mg/m2 daily for 3 days), and high-dose rituximab. For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m2 daily for 4 days), fludarabine (30 mg/m2 daily for 2 days), and cytarabine (1,000 mg/m2 daily for 2 days). Tacrolimus and methotrexate were used for graft-versus-host disease prophylaxis.
The median age was 56.5 years. Patients underwent a median of three prior chemotherapy regimens. Prior autologous transplantation failed in five (28%) patients and 16 (89%) had chemosensitive disease. Donor cell engraftment occurred in all patients. Eight patients (44%) required no platelet or RBC transfusion, and acute graft-versus-host disease of greater than grade 2 did not develop in any patient. The day-100 mortality was 0%. Complete remission (CR) occurred in 17 patients. Three patients progressed, and one was reinduced into continuous CR with donor lymphocyte infusion. With a median follow-up period of 26 months, the actuarial probability of current-event-free-survival at 3 years was 82% (95% CI, 65% to 99%).
Our data suggest that nonablative allogeneic transplantation is a safe and potentially effective strategy for patients with relapsed and chemosensitive mantle-cell lymphoma.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2003.05.501</identifier><identifier>PMID: 14645431</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Combined Modality Therapy ; Female ; Graft Survival ; Graft vs Host Disease - epidemiology ; Graft vs Host Disease - prevention & control ; Graft vs Tumor Effect ; Hematologic and hematopoietic diseases ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunosuppressive Agents - therapeutic use ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, Mantle-Cell - mortality ; Lymphoma, Mantle-Cell - therapy ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - therapy ; Remission Induction ; Survival Rate ; Tacrolimus - therapeutic use ; Transplantation Conditioning ; Transplantation, Homologous ; Treatment Outcome ; Tumors</subject><ispartof>Journal of clinical oncology, 2003-12, Vol.21 (23), p.4407-4412</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-5b8f96f6d795e5adc3662ac20a01970a38d965d3fb58c0e8a85c8de5c5e402123</citedby><cites>FETCH-LOGICAL-c421t-5b8f96f6d795e5adc3662ac20a01970a38d965d3fb58c0e8a85c8de5c5e402123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15363133$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14645431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KHOURI, Issa F</creatorcontrib><creatorcontrib>LEE, Ming-S</creatorcontrib><creatorcontrib>CHAMPLIN, Richard E</creatorcontrib><creatorcontrib>SALIBA, Rima M</creatorcontrib><creatorcontrib>GU JUN</creatorcontrib><creatorcontrib>FAYAD, Luis</creatorcontrib><creatorcontrib>YOUNES, Anas</creatorcontrib><creatorcontrib>PRO, Barbara</creatorcontrib><creatorcontrib>ACHOLONU, Sandra</creatorcontrib><creatorcontrib>MCLAUGHLIN, Peter</creatorcontrib><creatorcontrib>KATZ, Ruth L</creatorcontrib><title>Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma.
Eighteen patients were treated in one of two consecutive trials. Thirteen patients underwent a conditioning regimen of fludarabine (30 mg/m2 daily for 3 days), cyclophosphamide (750 mg/m2 daily for 3 days), and high-dose rituximab. For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m2 daily for 4 days), fludarabine (30 mg/m2 daily for 2 days), and cytarabine (1,000 mg/m2 daily for 2 days). Tacrolimus and methotrexate were used for graft-versus-host disease prophylaxis.
The median age was 56.5 years. Patients underwent a median of three prior chemotherapy regimens. Prior autologous transplantation failed in five (28%) patients and 16 (89%) had chemosensitive disease. Donor cell engraftment occurred in all patients. Eight patients (44%) required no platelet or RBC transfusion, and acute graft-versus-host disease of greater than grade 2 did not develop in any patient. The day-100 mortality was 0%. Complete remission (CR) occurred in 17 patients. Three patients progressed, and one was reinduced into continuous CR with donor lymphocyte infusion. With a median follow-up period of 26 months, the actuarial probability of current-event-free-survival at 3 years was 82% (95% CI, 65% to 99%).
Our data suggest that nonablative allogeneic transplantation is a safe and potentially effective strategy for patients with relapsed and chemosensitive mantle-cell lymphoma.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Graft Survival</subject><subject>Graft vs Host Disease - epidemiology</subject><subject>Graft vs Host Disease - prevention & control</subject><subject>Graft vs Tumor Effect</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, Mantle-Cell - mortality</subject><subject>Lymphoma, Mantle-Cell - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Remission Induction</subject><subject>Survival Rate</subject><subject>Tacrolimus - therapeutic use</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0U1PGzEQgGELgSAFzr1Ve4GeNvHX7DrHKCr9UCgSpVIPSNbEO0sWedepvaHi39cokTjN5ZmR9Zqxj4JPheR89mN5N81TTTlMgYsjNhEg67KuAY7ZhNdKlsKoP2fsQ0rPnAttFJyyM6ErDVqJCXv8GQZcexy7FyoW3ocnGqhzxa-R-nJJ3hcPEYe09TiMGYWhaEMsFs0LDo6a2T25XYw0jMVtBp72K6vXfrsJPV6wkxZ9osvDPGe_b748LL-Vq7uv35eLVem0FGMJa9POq7Zq6jkQYONUVUl0kiMX85qjMs28gka1azCOk0EDzjQEDkhzKaQ6Z9f7u9sY_u4ojbbvkssvwYHCLtlaaFmZ2mQ420MXQ0qRWruNXY_x1Qpu34LaHNS-BbUcbA6aNz4dTu_WPTXv_lAwg6sDwOTQt7mW69K7A1VlpbL7vHeb7mnzr4tkU4_e57PSPrsghZXKap2_7D_PZ4tj</recordid><startdate>20031201</startdate><enddate>20031201</enddate><creator>KHOURI, Issa F</creator><creator>LEE, Ming-S</creator><creator>CHAMPLIN, Richard E</creator><creator>SALIBA, Rima M</creator><creator>GU JUN</creator><creator>FAYAD, Luis</creator><creator>YOUNES, Anas</creator><creator>PRO, Barbara</creator><creator>ACHOLONU, Sandra</creator><creator>MCLAUGHLIN, Peter</creator><creator>KATZ, Ruth L</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031201</creationdate><title>Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma</title><author>KHOURI, Issa F ; LEE, Ming-S ; CHAMPLIN, Richard E ; SALIBA, Rima M ; GU JUN ; FAYAD, Luis ; YOUNES, Anas ; PRO, Barbara ; ACHOLONU, Sandra ; MCLAUGHLIN, Peter ; KATZ, Ruth L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-5b8f96f6d795e5adc3662ac20a01970a38d965d3fb58c0e8a85c8de5c5e402123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Graft Survival</topic><topic>Graft vs Host Disease - epidemiology</topic><topic>Graft vs Host Disease - prevention & control</topic><topic>Graft vs Tumor Effect</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, Mantle-Cell - mortality</topic><topic>Lymphoma, Mantle-Cell - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Remission Induction</topic><topic>Survival Rate</topic><topic>Tacrolimus - therapeutic use</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KHOURI, Issa F</creatorcontrib><creatorcontrib>LEE, Ming-S</creatorcontrib><creatorcontrib>CHAMPLIN, Richard E</creatorcontrib><creatorcontrib>SALIBA, Rima M</creatorcontrib><creatorcontrib>GU JUN</creatorcontrib><creatorcontrib>FAYAD, Luis</creatorcontrib><creatorcontrib>YOUNES, Anas</creatorcontrib><creatorcontrib>PRO, Barbara</creatorcontrib><creatorcontrib>ACHOLONU, Sandra</creatorcontrib><creatorcontrib>MCLAUGHLIN, Peter</creatorcontrib><creatorcontrib>KATZ, Ruth L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KHOURI, Issa F</au><au>LEE, Ming-S</au><au>CHAMPLIN, Richard E</au><au>SALIBA, Rima M</au><au>GU JUN</au><au>FAYAD, Luis</au><au>YOUNES, Anas</au><au>PRO, Barbara</au><au>ACHOLONU, Sandra</au><au>MCLAUGHLIN, Peter</au><au>KATZ, Ruth L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2003-12-01</date><risdate>2003</risdate><volume>21</volume><issue>23</issue><spage>4407</spage><epage>4412</epage><pages>4407-4412</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma.
Eighteen patients were treated in one of two consecutive trials. Thirteen patients underwent a conditioning regimen of fludarabine (30 mg/m2 daily for 3 days), cyclophosphamide (750 mg/m2 daily for 3 days), and high-dose rituximab. For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m2 daily for 4 days), fludarabine (30 mg/m2 daily for 2 days), and cytarabine (1,000 mg/m2 daily for 2 days). Tacrolimus and methotrexate were used for graft-versus-host disease prophylaxis.
The median age was 56.5 years. Patients underwent a median of three prior chemotherapy regimens. Prior autologous transplantation failed in five (28%) patients and 16 (89%) had chemosensitive disease. Donor cell engraftment occurred in all patients. Eight patients (44%) required no platelet or RBC transfusion, and acute graft-versus-host disease of greater than grade 2 did not develop in any patient. The day-100 mortality was 0%. Complete remission (CR) occurred in 17 patients. Three patients progressed, and one was reinduced into continuous CR with donor lymphocyte infusion. With a median follow-up period of 26 months, the actuarial probability of current-event-free-survival at 3 years was 82% (95% CI, 65% to 99%).
Our data suggest that nonablative allogeneic transplantation is a safe and potentially effective strategy for patients with relapsed and chemosensitive mantle-cell lymphoma.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>14645431</pmid><doi>10.1200/JCO.2003.05.501</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2003-12, Vol.21 (23), p.4407-4412 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71426878 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Combined Modality Therapy Female Graft Survival Graft vs Host Disease - epidemiology Graft vs Host Disease - prevention & control Graft vs Tumor Effect Hematologic and hematopoietic diseases Hematopoietic Stem Cell Transplantation Humans Immunosuppressive Agents - therapeutic use Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Mantle-Cell - mortality Lymphoma, Mantle-Cell - therapy Male Medical sciences Middle Aged Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - therapy Remission Induction Survival Rate Tacrolimus - therapeutic use Transplantation Conditioning Transplantation, Homologous Treatment Outcome Tumors |
| title | Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A22%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nonablative%20Allogeneic%20Stem-Cell%20Transplantation%20for%20Advanced/Recurrent%20Mantle-Cell%20Lymphoma&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=KHOURI,%20Issa%20F&rft.date=2003-12-01&rft.volume=21&rft.issue=23&rft.spage=4407&rft.epage=4412&rft.pages=4407-4412&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2003.05.501&rft_dat=%3Cproquest_cross%3E71426878%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71426878&rft_id=info:pmid/14645431&rfr_iscdi=true |